search
AI scientist
Trends
- 1Yann LeCun calls Anthropic CEO Dario Amodei 'deluded' over AI risks●AI ‘godfather’ Yann LeCun: Anthropic CEO Dario Amodei is ‘deluded,’ ‘crazy,’ and doesn’t understand cybersecurity
Meta's chief AI scientist Yann LeCun publicly attacked Anthropic CEO Dario Amodei, calling him 'deluded,' 'crazy,' and claiming he does not understand cybersecurity. The clash highlights the deepening split among leading AI researchers over how dangerous advanced AI systems really are, with LeCun dismissing the doomsday warnings that Anthropic's leadership often emphasizes while promoting his own more skeptical view.
- 2
A new discussion is circulating on whether artificial intelligence has cracked one of mathematics' most difficult open problems. The claim is being debated by scientists and enthusiasts, with Neil deGrasse Tyson's StarTalk programme weighing in on what the reported breakthrough would mean for maths and for the future of AI research. Details of the specific problem and the claimed proof remain limited in the coverage.
- 3
Anthropic has published a research essay titled 'Claude-Shaped Science', exploring how its AI assistant Claude is influencing the way scientific work is conducted and shaped. The piece is drawing attention on Hacker News, where readers are debating what it means for research when AI tools increasingly mediate how scientists write, think and run their work.
- 4AI doomerism's bad science serves big business●How the bad science of AI doomerism is good for big business
The Bulletin of the Atomic Scientists argues that apocalyptic claims about artificial intelligence wiping out humanity rest on weak science, and that the companies spreading these warnings benefit from them. By framing existential risk as the main AI danger, the argument goes, firms divert attention from present harms, regulation, and accountability, while positioning themselves as the only ones capable of building safe AI.
- 5NASA and IBM release open-source AI model for lunar science●NASA and IBM's open source lunar model turns 17 years of orbiter data into a foundation for lunar science
NASA and IBM have released an open-source AI foundation model trained on 17 years of data from lunar orbiters. The model is designed to help researchers study the Moon's surface, supporting tasks like analyzing terrain and planning future missions. By making it freely available, the agencies aim to lower barriers for lunar scientists and accelerate discovery as interest in Moon exploration grows worldwide.
- 6Scientist Suggests Making AI Believe in God to Keep Humans Safe●The panic over AI has been pretty stupid, but I didn't think it would get this stupid. Also, maybe watch Battlestar Gala
A scientist argues that artificial intelligence systems could be made to believe in God as a way of keeping them safe for humanity. The proposal, flagged by physicist Sabine Hossenfelder, is drawing mockery and debate online, with commenters dismissing it as another example of irrational AI panic and joking that people should instead watch Battlestar Galactica, which explored similar themes.
- 7Nuclear science magazine calls AI doomerism bad science▼Nuclear doomsday mag says, AI Doomerism is bad science
The Bulletin of the Atomic Scientists, long known for its Doomsday Clock warning about nuclear risk, has published an argument that AI doomerism amounts to bad science. The piece pushes back on claims that artificial intelligence poses existential threats, framing such fears as unsupported by evidence. It has drawn attention in discussions about whether AI alarmism distracts from more concrete technological and nuclear dangers.
- 8UAE scientists use AI to discover potential blood cancer drug▼UAE scientists harness AI to discover potential blood cancer drug
Scientists in the United Arab Emirates have used artificial intelligence to identify a potential new drug for blood cancer. The development highlights the growing role of AI in accelerating drug discovery, and coverage from The National has drawn attention to the UAE's expanding research sector. Details of the compound and clinical stage were not provided.